Novo Nordisk already has a fairly well-stocked pipeline of candidates, but one of its near-term hopes – CagriSema, which combines semaglutide with dual amylin and calcitonin receptor agonist ...

Streamlined access to authentic, FDA-approved, rigorously-tested Zepbound comes from Sesame's direct integration with Gifthealth. Zepbound is the first and only FDA-approved dual glucagon-like peptide ...

Novo Nordisk said Monday that it had entered into a license agreement with a Chinese company developing a competitor to ...

Mounjaro, a newly launched weight-loss and diabetes drug, is now available in India. Developed by Eli Lilly, it promises more effectiveness than Ozempic and comes at a lower cost. Experts believe it ...

A single-dose vial of Mounjaro costs Rs. 3,500 for 2.5 mg or Rs. 4,375 for 5 mg. On a typical weekly dose, that adds up to ...

Semaglutide is already available in Ireland through diabetes medication Ozempic. However, its producer Novo Nordisk uses the ...

The first year of the pandemic was historic not only for COVID-19, but for a surprising side effect — the health system known ...

Novo Nordisk on Monday announced a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the ...

Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...

A Call for Scrutiny on Weight-Loss Medications** Concerns are mounting as one man's alarming experience with the weight-loss drug Ozempic brings to light the urgent need for scrutiny over the safety ...

North Carolina State Treasurer Brad Briner spoke with WRAL News about plans to tackle the state health plan deficit, bringing ...

Plenty of folks have been using GLP-1s — generic versions of popular weight loss drugs such as Ozempic and Zepbound — to jump ...